Way back at the beginning of the year while attending the JP Morgan Healthcare conference we asked Dave Ricks Lilly’s (NYSE: LLY) CEO how the company planned to deal with the launch of Amedlog from Sanofi (NYSE: SNY). We asked simply why Sanofi would not do to Lilly in the short-acting insulin space with Amedlog what Lilly had done to Sanofi in the long-acting segment with Basaglar. The answer was underwhelming with Mr. Ricks basically saying he wasn’t that worried. Well he should be.
On Friday Sanofi reported results and during the call CEO Olivier Brandicourt . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.